The PennZone

PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone

• DayPass launches in ChatGPT and Claude
• Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
• Victor Archibong Expands ItsArchiDuh Creator Brand
• Talented Learning Unveils 2026 LMS Award Winners
• Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone

• ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
• Revinate launches hospitality's first data activation platform
• HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
• BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
• Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).